Drugs / TB-PPD
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02336542 | Nov 2014 → Jul 2015 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07152639 | Aug 2025 → May 2026 overdue | tuberculosis | Chengdu CoenBiotech Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT03027154 | Oct 2016 → Oct 2017 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02623556 | Dec 2015 → Mar 2018 | tuberculosis | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05746611 | Apr 2023 → May 2024 | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TB-PPD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02336542 ↗ |
| Known as | tuberculin purified protein derivative | “Inject intradermally ESAT6-CFP10 and TB-PPD(tuberculin purified protein derivative ) in different arms of the same subject.” NCT02336542 ↗1“TB-PPD (tuberculin purified protein derivative)” NCT02623556 ↗ |
| Modality | Diagnostic / imaging agent | “clinical auxiliary diagnosis of tuberculosis” NCT02336542 ↗ |
| Route | Other | “inject intradermally” NCT02623556 ↗ |